Glatiramer Acetate CAS No. 147245-92-9 Peptide CAS NO.158861-67-7
- FOB Price: USD: 15.00-15.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: T/T,Other
- Available Specifications:
pharmaceutical grade(1-1000)Gram
- Product Details
Keywords
- Peptides
- Pharmaceutical Intermediate
- Chemical
Quick Details
- ProName: Glatiramer Acetate CAS No. 147245-92-9...
- CasNo: 158861-67-7
- Molecular Formula: C46h65n13o11s2
- Appearance: White Powder
- Application: bodybuilding pharmaceutical material, ...
- DeliveryTime: 3days
- PackAge: Packaging can be according to customer
- Port: Shanghai
- ProductionCapacity: 10000 Metric Ton/Day
- Purity: 99%
- Storage: Keep it under seal in cool and dark pl...
- Transportation: FEDEX DHL TNT UPS EUB
- LimitNum: 1 Gram
- Related Substances: Peptides
- Residue on Ignition: 0
- Heavy Metal: 0
- Valid Period: 2years
- CasNo: 158861-67-7
- Molecular Formula: C46h65n13o11s2
- Appearance: detailed see specifications
- Purity: 99%
- Grade: Grade
- LimitNum: 1 Gram
Superiority
This is Allen from Zhengzhou Filter Biotechnology Co.,Ltd.We are the professional supplier of peptide products in China over 10 years. we have Professional Lab to confirm the Quality and Serive for all clients in long-term run cooperation.
Our Company as a Pharmaceutical Raw Material Manufacturer specialize in R&D the New Drugs and Producing the Generic Medicine:
Amino Acids&Vitamins
Pharmaceutical Polypeptide,
Comestic Polypeptide,
Veterinary Peptide and
Pharmaceutical APIs.
Due to of the high quality and good service, They have been exported more than 30 countries.
Sincerely hope to have a chance to cooperate with you
Details
Description
latiramer acetate (also known as Copolymer 1, Cop-1, or Copaxone - as marketed by Teva Pharmaceuticals) is animmunomodulator drug currently used to treat multiple sclerosis. It is a random polymer of four amino acids found inmyelin basic protein, namely glutamic acid, lysine, alanine, and tyrosine, and may work as a decoy for the immune system. Glatiramer acetate is approved by the Food and Drug Administration (FDA) for reducing the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability.
Although the clinical definition of multiple sclerosis requires two or more episodes of symptoms and signs, glatiramer acetate is approved for treatment after single episodes. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.